A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy

William D. Erwin; Mark W. Groch; Daniel J. Macey; Gerald L Denardo; Sally J. DeNardo; Sui Shen

doi:10.1016/0969-8051(96)00036-4

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy

William D. Erwin, Mark W. Groch, Daniel J. Macey, Gerald L Denardo, Sally J. DeNardo, Sui Shen

Research

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

A treatment planning program for radioimmunotherapy employing quantitative Anger camera imaging and the MIRD formalism has been designed and implemented on a clinical nuclear medicine computer. Radionuclide residence times are calculated from linear, mono- and bi-exponential, and cubic spline fits to regional activity versus time curves, and radiation-absorbed dose estimates for all target organs for ¹³¹I, ⁶⁷Cu, and 58 other radionuclides can be calculated. This software has been successfully applied to radioimmunotherapy of B-cell malignancies and breast adenocarcinomas.

Original language	English (US)
Pages (from-to)	525-532
Number of pages	8
Journal	Nuclear Medicine and Biology
Volume	23
Issue number	4
DOIs	https://doi.org/10.1016/0969-8051(96)00036-4
State	Published - May 1996

Keywords

Dosimetry
MIRD
Monoclonal antibodies
Radioimmunoimaging
Radioimmunotherapy
Treatment planning

ASJC Scopus subject areas

Molecular Medicine
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/0969-8051(96)00036-4

Cite this

@article{2b23100a91d14621a454884dbfa85679,

title = "A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy",

abstract = "A treatment planning program for radioimmunotherapy employing quantitative Anger camera imaging and the MIRD formalism has been designed and implemented on a clinical nuclear medicine computer. Radionuclide residence times are calculated from linear, mono- and bi-exponential, and cubic spline fits to regional activity versus time curves, and radiation-absorbed dose estimates for all target organs for 131I, 67Cu, and 58 other radionuclides can be calculated. This software has been successfully applied to radioimmunotherapy of B-cell malignancies and breast adenocarcinomas.",

keywords = "Dosimetry, MIRD, Monoclonal antibodies, Radioimmunoimaging, Radioimmunotherapy, Treatment planning",

author = "Erwin, {William D.} and Groch, {Mark W.} and Macey, {Daniel J.} and Denardo, {Gerald L} and DeNardo, {Sally J.} and Sui Shen",

year = "1996",

month = may,

doi = "10.1016/0969-8051(96)00036-4",

language = "English (US)",

volume = "23",

pages = "525--532",

journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy

AU - Erwin, William D.

AU - Groch, Mark W.

AU - Macey, Daniel J.

AU - Denardo, Gerald L

AU - DeNardo, Sally J.

AU - Shen, Sui

PY - 1996/5

Y1 - 1996/5

N2 - A treatment planning program for radioimmunotherapy employing quantitative Anger camera imaging and the MIRD formalism has been designed and implemented on a clinical nuclear medicine computer. Radionuclide residence times are calculated from linear, mono- and bi-exponential, and cubic spline fits to regional activity versus time curves, and radiation-absorbed dose estimates for all target organs for 131I, 67Cu, and 58 other radionuclides can be calculated. This software has been successfully applied to radioimmunotherapy of B-cell malignancies and breast adenocarcinomas.

AB - A treatment planning program for radioimmunotherapy employing quantitative Anger camera imaging and the MIRD formalism has been designed and implemented on a clinical nuclear medicine computer. Radionuclide residence times are calculated from linear, mono- and bi-exponential, and cubic spline fits to regional activity versus time curves, and radiation-absorbed dose estimates for all target organs for 131I, 67Cu, and 58 other radionuclides can be calculated. This software has been successfully applied to radioimmunotherapy of B-cell malignancies and breast adenocarcinomas.

KW - Dosimetry

KW - MIRD

KW - Monoclonal antibodies

KW - Radioimmunoimaging

KW - Radioimmunotherapy

KW - Treatment planning

UR - http://www.scopus.com/inward/record.url?scp=0030152864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030152864&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(96)00036-4

DO - 10.1016/0969-8051(96)00036-4

M3 - Article

C2 - 8832711

AN - SCOPUS:0030152864

VL - 23

SP - 525

EP - 532

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 4

ER -

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this